Vision Retirement LLC Raises Position in Stryker Corporation $SYK

Vision Retirement LLC raised its position in shares of Stryker Corporation (NYSE:SYK) by 1,321.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 10,944 shares of the medical technology company’s stock after acquiring an additional 10,174 shares during the period. Stryker makes up approximately 1.0% of Vision Retirement LLC’s holdings, making the stock its 22nd largest holding. Vision Retirement LLC’s holdings in Stryker were worth $3,596,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp raised its holdings in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its position in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the period. Finally, Norges Bank bought a new stake in shares of Stryker during the 4th quarter valued at $1,822,272,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last three months. Insiders own 4.60% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Stryker Price Performance

SYK opened at $319.78 on Friday. The firm has a market cap of $122.59 billion, a PE ratio of 37.01, a P/E/G ratio of 2.05 and a beta of 0.77. The stock has a 50-day moving average price of $312.69 and a 200-day moving average price of $336.82. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on SYK shares. Citigroup reduced their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Canaccord Genuity Group decreased their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, BTIG Research set a $371.00 price target on Stryker in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.